Citigroup Inc Albireo Pharma, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$18.01 - $23.78 $6,069 - $8,013	-337 Reduced 37.44%	563 $12,000
Q3 2022 Nov 10, 2022	SELL	$16.32 - $26.37 $953,463 - $1.54 Million	-58,423 Reduced 98.48%	900 $17,000
Q2 2022 Aug 10, 2022	BUY	$18.54 - $37.29 $937,864 - $1.89 Million	50,586 Added 578.99%	59,323 $1.18 Million
Q1 2022 May 12, 2022	SELL	$23.94 - $33.74 $1.04 Million - $1.47 Million	-43,449 Reduced 83.26%	8,737 $261,000
Q4 2021 Feb 10, 2022	BUY	$21.19 - $31.29 $510,403 - $753,682	24,087 Added 85.72%	52,186 $1.22 Million
Q3 2021 Nov 10, 2021	BUY	$27.36 - $35.98 $768,788 - $1.01 Million	28,099 New	28,099 $877,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.